Searched for
PHRAMA
ED raids in 'illegal' drugs sale case by Punjab de-addiction centresThe Enforcement Directorate conducted raids in Punjab and Mumbai. This action relates to a money laundering investigation. The probe focuse...- Cabinet approves foreign investment of up to Rs 9,589 crore in Suven PharmaThe Cabinet Committee on Economic Affairs has approved foreign investment of up to Rs 9,589 crore in Suven Pharmaceuticals by Cyprus-based ...
- D-Street at new high but these 11 Nifty stocks still available at 2022 levelsNifty has witnessed a rise of approximately 4% in the year 2023 so far, and among the Nifty50 pack, 39 stocks have shown positive returns b...
- Macquarie initiates coverage on Mankind Pharma, sees 30% upsideMankind Pharma derives 98% of its revenue from the domestic pharma market. Within its domestic business, 90% of its revenue comes from pres...
- Trading Guide: Wipro among 3 stock recommendations for Friday
- After rallying 52% in a month, can Piramal Enterprises sustain its momentum?The company’s management has guided for a 15% organic revenue growth in the pharma business for FY22 compared with the 1% growth in the fir...
- Trending stocks: Glenmark Pharma shares down nearly 1%A total of 111,943 shares changed hands on the counter till 10:06AM.
- Nifty tops 12,000, Sensex scales fresh all-time highBroader market indices traded in tandem with their headline peers.
- Sensex, Nifty settle flat as investors take profitAsian shares lost their footing after Chinese data signalled further weakness in the economy.
- NPPA fixes prices of 22 drug formulationsWhile National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices of 20 formulations, it has also capped the ceiling prices of...
- How Birla Sun Life equity fund outperformed in multiple periodsBirla Sun Life Equity has distinguished itself as the only one which has been in the top 3 best performing schemes in the past 1-, 3 and 5-...
- Sectoral churning behind recent correction in pharma stocks; present valuations look attractive: Gaurav MehtaQuality pharma names were commanding a hefty premium, which was perhaps a little unsustainable, says Mehta.
- Markets have bottomed out, but need bigger triggers for an upside: K Ramanathan"I see a range-bound market, at least in the near term. Surely, the upside is capped because the pace of recovery is expected to be pretty ...
- Pharma majors urges for separate zone in J&K to tap bigger off shore marketsPharma majors operating manufacturing facilities in Jammu want a separate, cleaner zone to enable them tapping better and bigger off shore ...
- HC provides relief to Pfizer on trade mark battle over COREXOn a plea by global pharma major Pfizer, the Delhi High Court today restrained Ahmedabad-based Stallion Laboratories from manufacturing and...
- Buy ABB and Areva T&D: Rohit ShindeRohit Shinde, Independent Analyst in an interview with ET Now talks about Areva T&D and ABB.
- Telangana unrest may impact fund flows: AssochamIndustry body Assocham on Saturday said the Telangana unrest will be detrimental for the growth of the state and may impact the flow of inv...
- GSK drug-deal talk lifts DRL scripShares of Dr Reddy’s Laboratories (DRL) touched an intra-day high of Rs 878.70, amid speculation that the Indian drug maker is in prelimina...
- CPM demands separate ministry for pharma sectorStating that the growth of the estimated 12-billion dollars pharmaceutical industry has been hampered by multiple authorities, UPA ally CPI...
- Ramky Group to invest Rs 500 cr in 3 pharma incubation centresHyderabad based infrastructure major Ramky group is set to invest Rs 500 crore in three pharma incubation centres in the country.
Load More
